Return-Path: <nifl-health@literacy.nifl.gov>
Received: from literacy (localhost [127.0.0.1]) by literacy.nifl.gov (8.10.2/8.10.2) with SMTP id g98GFCX00089; Tue, 8 Oct 2002 12:15:12 -0400 (EDT)
Date: Tue, 8 Oct 2002 12:15:12 -0400 (EDT)
Message-Id: <OF48F5BA8C.44ED006C-ON85256C4C.00580AE5@notes.duke.edu>
Errors-To: listowner@literacy.nifl.gov
Reply-To: nifl-health@literacy.nifl.gov
Originator: nifl-health@literacy.nifl.gov
Sender: nifl-health@literacy.nifl.gov
Precedence: bulk
From: "Kerry Harwood" <harwo001@mc.duke.edu>
To: Multiple recipients of list <nifl-health@literacy.nifl.gov>
Subject: [NIFL-HEALTH:3791] Re: primary peritoneal cancer and the tumor marker CA-125
X-Listprocessor-Version: 6.0c -- ListProcessor by Anastasios Kotsikonas
Content-type: text/plain; charset=us-ascii
X-Mailer: Lotus Notes Release 5.0.7 March 21, 2001
Status: O
Content-Length: 3391
Lines: 95
This website is a comprehensive FAQ on CA-125 and ovarian cancer screening.
While doing the test is simple, interpretation can be difficult as there
are many non-cancer conditions that lead to elevated CA-125. In addition,
the test is less likely to pick up early cancers and to pick up cancers in
younger women, two situations you'd especially like an effective screening
tool. The text below the URL is from the National Cancer Institute's
website.
Kerry Harwood, RN, MSN
Director, Cancer Patient Education Program
Duke University Health System
FAQ on CA-125 in ovarian cancer
http://pathology2.jhu.edu/ovca/ca125q&a.cfm
>From NCI:
CA 125
CA 125 is produced by a variety of cells,
but particularly by ovarian cancer cells.
Studies have shown that many women with
ovarian cancer have elevated CA 125
levels. CA 125 is used primarily in the
management of treatment for ovarian
cancer. In women with ovarian cancer being
treated with chemotherapy, a falling
CA 125 level generally indicates that the
cancer is responding to treatment.
Increasing CA 125 levels during or after
treatment, on the other hand, may
suggest that the cancer is not responding
to therapy or that some cancer cells
remain in the body. Doctors may also use CA
125 levels to monitor patients for
recurrence of ovarian cancer.
Not all women with elevated CA 125 levels
have ovarian cancer. CA 125 levels
may also be elevated by cancers of the
uterus, cervix, pancreas, liver, colon,
breast, lung, and digestive tract.
Noncancerous conditions that can cause elevated
CA 125 levels include endometriosis, pelvic
inflammatory disease, peritonitis,
pancreatitis, liver disease, and any
condition that inflames the pleura (the tissue
that surrounds the lungs and lines the
chest cavity). Menstruation and pregnancy
can also cause an increase in CA 125.
"Daphen Greenberg" <epedgg@panther.Gsu.EDU>@nifl.gov on 10/08/2002 11:55:46
AM
Please respond to nifl-health@nifl.gov
Sent by: nifl-health@nifl.gov
To: Multiple recipients of list <nifl-health@literacy.nifl.gov>
cc:
Subject: [NIFL-HEALTH:3790] primary peritoneal cancer and the tumor
marker CA-125 blood test
There has been an email floating around about primary peritoneal cancer and
the tumor marker CA-125 blood test. I am hoping that the medical
professionals on this listserv can shed some insight into this, so that we
can know how to direct our learners. According to the email, one out of
every 55 women will get ovarian or primary peritoneal cancer and it is
urged
that women ask their doctors to run the CA-125 blood test as part of an
annual physical exam. Apparently, this blood test is inexpensive and
simple.
Is there anyone on this listserv who can shed light on this and do you know
of easy to read websites or printed materials that discuss this?
Thanks!
Daphne Greenberg
Georiga State University
This archive was generated by hypermail 2b30 : Fri Jan 17 2003 - 14:41:35 EST